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Abstract
High mobility group box 1 protein (HMGB1), a nuclear protein, can be translocated to the cytoplasm and secreted in colon
cancer cells. However, the diagnostic significance of HMGB1 has not been evaluated in colorectal carcinomas. For this
purpose, we have screened the expression and secretion of HMGB1 in 10 colon cancer cell lines and 1 control cell line and
found that HMGB1 was detected in the culture medium. To evaluate the diagnostic value of HMGB1, we performed an
enzyme-linked immunosorbent assay to measure HMGB1 levels and compared them to carcinoembryonic antigen (CEA)
levels in the serum samples of 219 colorectal carcinoma patients and 75 healthy control subjects. We found that the serum
HMGB1 level was increased by 1.5-fold in patients with colorectal carcinoma compared to those in healthy controls. When
HMGB1 and CEA levels were compared, HMGB1 had similar efficacy as CEA regarding cancer detection (the sensitivity was
20.1% for HMGB1 vs. 25.6% for CEA, and the specificity was 96% for HMGB1 vs. 90.7% for CEA). Moreover, the diagnostic
accuracy of HMGB1 for stage I cancer was significantly higher than that of CEA (sensitivity: 41.2% vs. 5.9%; specificity: 96%
vs. 90.7). When we combined HMGB1 and CEA, the overall diagnostic sensitivity was higher than that of CEA alone (42% vs.
25.6%), and the diagnostic sensitivity for stage I was also elevated (47% vs. 5.9%). However, the prognosis of patients was
not related with serum HMGB1 concentrations. Our findings indicate that serum HMGB1 levels are increased in a subset of
colorectal carcinomas, suggesting their potential utility as a supportive diagnostic marker for colorectal carcinomas.
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Introduction
High mobility group (HMG) proteins primarily reside in the
nucleus and regulate gene expression by binding to DNA without
any sequence specificity [1]. One such HMG protein, high
mobility group box-1 (HMGB1), consists of an 80-amino acid A
Box, a B Box, and an acidic carboxyl tail. Similarly as other
members of its family, HMGB1 binds to the minor groove of DNA
in a non-sequence-specific manner [2,3] and is involved in DNA
structural and transcriptional regulation. Nuclear localization of
HMGB1 and its affinity for DNA are reported to be regulated by
phosphorylation [4] and acetylation [3,5].
A relationship has been suggested between HMGB1 and cancer
based on findings that HMGB1 regulates the transcription of
many cancer genes, such as E-selectin, TNF-a, insulin receptor, and
BRCA1 [6,7,8]. Another report suggested that extracellular
HMGB1, secreted by necrotic cancer cells, might contribute to
cancer cell survival, proliferation, and invasion [9]. The
association of HMGB1 overexpression and poor prognosis has
been reported in cancer patients [9,10,11,12,13]. In addition to
these reports, recent evidence demonstrated that mice with
chemically induced colitis exhibited elevated levels of serum
HMGB1, and antibody-mediated neutralization of serum
HMGB1 decreased the frequency of cancer formation [11]. All
of these results suggest that HMGB1 is an important mediator for
cancer transformation, cancer growth, and invasion.
HMGB1 secretion and its binding to cell membrane receptors
including the receptor for advanced glycation end products
(RAGE) appear to be important in cancer progression [14]. The
secretion of HMGB1 has been reported in the cells of several
malignancies including glioma, colon cancer, lung cancer, and
melanoma [15,16,17,18]. In addition to these reports, HMGB1
has been detected in the sera of patients with various cancers,
including cervical, lung, gastric, and liver cancers
[19,20,21,22,23]. Despite the detection of HMGB1 in the sera
of cancer patient, the clinical evaluation of HMGB1 was not
performed in these cancers except for gastric and cervical cancer.
The diagnostic sensitivity and specificity of HMGB1 were; 71%
and 67% in gastric cancer and 71.6% and 78% in cervical cancer,
respectively. Although HMGB1 overexpression has been reported
in colon cancer by the percentage over 90% [17,24], the serum
level of HMGB1 and its clinical significance have not been
reported. To evaluate the diagnostic significance of secreted
HMGB1 in vivo, we performed an ELISA assay using blood
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samples from 219 colorectal carcinoma patients and compared the
values to those of 75 non-cancerous controls. We herein
demonstrated that HMGB1 is present in the blood of colorectal
carcinoma patients, suggesting its utility in the early diagnosis of
colorectal carcinomas.
Methods
Cells and media
Eleven cell lines, including a cell line derived from normal
colonic mucosa (CCD18Co) and 10 cell lines derived from colon
cancers (HCT116, LS174T, RKO, DLD-1, LoVo, HCT-8,
SW480, SW620, HT-29, and WIDR), were obtained from either
the American Type Culture Collection (ATCC, Manassas, VA;
http://www.atcc.org) or the Korean Cell Line Bank (KCLB,
Seoul, Korea; http://cellbank.snu.ac.kr). Cells were grown in
RPMI1640, Dulbecco’s modified Eagle’s medium, or modified
essential medium supplemented with 10% fetal bovine serum (Life
Technologies, Grand Island, New York), penicillin, and strepto-
mycin at 37uC in a humidified 5% CO2 environment.
Concentration of secreted proteins
To collect secreted proteins, cells were incubated with serum
free media for 1 day before harvesting, and the culture medium
was collected and concentrated using iCON 9K concentrators
(Thermo Fisher Scientific, Rockford, IL).
Patient selection and tissue and blood specimen
collection
To test serum HMGB1 levels, fresh blood samples from 219
colorectal carcinoma patients and 75 hospital-based healthy
controls without evidence of colorectal carcinomas were used.
All the samples were collected from 2004 to 2006 and stored in the
Liver Cancer Specimen Bank of the Korea Science and
Engineering Foundation of the Ministry of Science and Technol-
ogy at Yonsei University, College of Medicine, Seoul, Korea.
Written informed consent was obtained from each patient, and the
Institutional Review Board of Severance Hospital and Yonsei
University, College of Medicine approved our study (IRB approval
No.GR-2007-001). Before blood sample preparation, all of the
cancer patients and healthy control subjects underwent colonos-
copy and other studies for the detection of malignancy. In the
patients who were pathologically confirmed with colorectal
carcinoma after colonoscopy, blood samples were collected one
day before surgery. The period of blood sample collection was not
exceeded two weeks after colonoscopy. In the controls who were
confirmed to have no evidence of colon cancer or other tumors,
blood samples were collected in the outpatient clinic. Again, the
period of blood sample collection was not exceeded two weeks
after colonoscopy. The control subjects were considered to have
no colorectal precancerous disease such as ulcerative colitis or
polyps by colonoscopy and laboratory test. No control subjects
have developed cancer during the follow up period. The
distribution of age and gender status was almost matched between
healthy control subjects and cancer patients, and the demograph-
ics were depicted in Table 1. After case selection, all the serum
specimens were analyzed without knowledge of disease status.
. All blood samples were delivered to the pathology laboratory
within 30 min after collection, and the serum was immediately
separated. For blood preparation, 3 cc of blood were collected in a
serum separation tube, and the serum was prepared as previously
described [25].
Western blot analysis
To compare serum HMGB1 levels between colorectal cancer
patients and healthy control subjects, we selected six colorectal
carcinoma serum samples and four healthy control samples.
Because of the limitation of blood volume in our cases, we selected
six colorectal carcinoma serum samples and four healthy control
samples according to the volume of collection. The top six most
abundant proteins (serum albumin, immunoglobulin G, immuno-
globulin A, transferrin, haptoglobin, and antitrypsin) were
depleted using MARS (Agilent Technology, Santa Clara, CA)
column. Serum (30 mL) was diluted 1:5 with a proprietary ‘‘Buffer
A’’ and loaded onto the MARS column. The unbound fraction
was concentrated by ultrafiltration using a Microcon filter (3000-
Da cutoff; Millipore, MA). Protein levels in depleted serum
samples were measured by the Bradford protein assay method,
and 5–10 mg of proteins were separated by 4–12% gradient
sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-
PAGE), transferred to nitrocellulose membranes, and blocked by
incubating the membranes at room temperature in tris buffered
saline-Tween-20 containing 5% skim milk. Rabbit polyclonal anti-
HMGB1 (Abcam, Cambridge, UK) antibody diluted 1:1000 in
blocking buffer was applied to membranes, which were incubated
overnight at 4uC. Membranes were washed, incubated for 1 h
with horseradish peroxidase-conjugated secondary antibody
(Santa Cruz Biotechnology, Santa Cruz, CA), washed again, and
developed with ECL-Plus (Amersham Pharmacia Biotech, Up-
psala, Sweden).
Immunohistochemistry
Serial sections from formalin-fixed, paraffin-embedded blocks of
120 colorectal cancer tissues obtained from patients who had not
received preoperative chemoradiotherapy were applied to 3-
aminopropyltriethoxysilane-coated slides (Sigma, St. Louis, MO).
Deparaffinization and rehydration were performed using xylene
and alcohol. The slides were pretreated in a microwave oven for
antigen retrieval. Sections were incubated for 30 min at room
temperature with antibodies against rabbit monoclonal anti-
HMGB1 (Epitomics, Burlingame, CA) at a dilution of 1:250. To
block endogenous peroxidase activity, slides were incubated with
blocking reagent (DAKO, Glostrup, Denmark) for 5 min before
incubation with the primary antibody for 30 min at 25uC. The
enzyme-conjugated polymer (EnVision, DAKO) and diaminoben-
zidine (DAKO) were used as a visualization system and
chromogen, respectively. HMGB1 expression was categorized as
expressed and negative; cases with definitive epithelial staining in
Table 1. The demographics of 75 healthy control subjects
and 219 colorectal cancer patients according to age and
gender.
Healthy (%) CRC (%)
Age
,60 35 (46.7) 101 (46.1)
$60 40 (53.3) 118 (53.9)
Sum 75 (100) 219 (100)
Gender
Male 47 (63) 137 (62.6)
Female 28 (37) 82 (37.4)
Sum 75 (100) 219 (100)
doi:10.1371/journal.pone.0034318.t001
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more than 10% of the tumor cells were categorized as expressed,
and cases with definite epithelial staining in less than 10% of the
tumor cells were categorized as negative.
ELISA
Serum concentrations of HMGB1 were evaluated by ELISA
using the HMGB1 ELISA Kit II (Shino-test, Tokyo, Japan).
ELISA was performed according to the manufacturer’s instruc-
tion. Serum concentrations of CEA were evaluated by chemilu-
miniscent immunoassay using ADVIA Centaur (Bayer Healthcare
LLC, NY, USA). All of the concentrations of HMGB1 and CEA
were measured in exactly same samples at a time.
Statistical analysis
Statistical analysis was performed using MedCalc for Windows,
v9.3.3.0 (MedCalc Software, Mariakerke, Belgium). To compare
the concentrations of HMGB1 and CEA in patients and healthy
controls, we calculated P-values for the average ELISA results by
an independent-samples t-test. We constructed receiver operating
characteristic (ROC) curves for serum HMGB1 and CEA, either
alone or in combination, to assess their diagnostic accuracy in
distinguishing colorectal carcinoma patients from normal control
subjects. Using the ROC method, we calculated the sensitivity,
specificity, error rate, and area under the curve (AUC) to
determine the diagnostic accuracy of our findings. The combina-
tion of CEA and HMGB1 was evaluated by logistic regression. We
also calculated P values to determine whether serum levels of
HMGB1 and CEA are related to the histopathologic and clinical
features of cancer patients. P values were calculated using the x2
test. The survival outcome was expressed by applying the Kaplan-
Meier method, and the log-rank test was used to compare the
prognostic significance of individual variables on survival.
Results
HMGB1 is overexpressed in colorectal cancer
To compare the expression levels of HMGB1 in colorectal
cancer tissues and adjacent normal mucosa, we firstly performed
an immunohistochemical experiment using paraffin-embedded
colorectal cancer tissues. All the cases should similar results in the
colon cancer. HMGB1 was expressed in the nuclei of both normal
and tumor cells (Figure S1). However, cytoplasmic HMGB1
expression was exclusively observed in tumor cells. The compar-
ison of HMGB1 expression between the tumors was not significant
because all of the tumor cells exhibited the same patterns of strong
nuclear expression and weak cytoplasmic expression.
HMGB1 is detected in the media of colon cancer cells and
the blood of cancer patients
To identify HMGB1 secretion in colon cancer cells, we
measured HMGB1 secretion in several colon cancer cells and
compared the levels to those in normal cell line (CCD18Co) by
western blot analysis. We observed diverse ranges of HMGB1
secretion levels in the 10 colon cancer cell lines (Figure 1A). In
contrast, there was no detectable level of HMGB1 in the media of
CCD18Co cells. Based on these results, we have performed the
western blot analysis for 10 serum samples to investigate whether
serum HMGB1 was detectable in patients and control subjects.
We firstly have depleted six abundant proteins in fresh serum by
MARS column. HMGB1 was detected in the serum, and HMGB1
levels were increased in colorectal cancer patients compared to
those in healthy control subjects. To calculate the ratio between
HMGB1 secretion levels in colorectal cancer patients and those in
healthy subjects, we quantified the band of western blot images by
densitometry, with normalization using CBB (Coomassie Brilliant
Blue) staining. By densitometry program, TINA, we have
calculated each ratio of HMGB1:CBB and re-calculated by
percentage. The mean value was 150.8610.3 (mean6SD) in
healthy controls and 175.5623.1 (mean6SD) in cancer patients
(P = 0.06). The median value was 151.9 (137.3, 162.0) in healthy
controls and 181.6 (140.7, 200.1) in cancer patients (P = 0.1141) by
the Wilcoxon rank-sum test. The median values were represented
by median (min, max). We demonstrated that serum HMGB1
expression was approximately 1.2-fold higher in colorectal cancer
patients than in healthy controls by the mean value, with high
diversity between patients (Figure 1B). These results suggest that
Figure 1. HMGB1 is secreted from colon cancer cells and
detected in the blood of cancer patients. HMGB1 in the culture
media of colon cancer cells (A) and the sera of colorectal cancer patients
(B) exhibited varying degrees of HMGB1 secretion. Culture media were
collected, concentrated using a specified column, and the blood
samples were depleted of the six most abundant proteins using a MARS
column. (A) Normal colon fibroblast cell line CCD18Co did not secrete
visible amounts of HMGB1 in the culture media; however most tumor
cells secreted HMGB1 with slight differences between tumor cells.
Coomassie Brilliant Blue staining indicated that equal amounts of
proteins were loaded onto SDS-PAGE gels. (B) Human serum proteins
were depleted, and HMGB1 secretion was examined. HMGB1 secretion
was observed in both healthy controls and colorectal cancer patients,
but elevated serum HMGB1 levels were noted in cancer patients. The
numbers provided for the cases match those in our tissue bank
database. N represents normal healthy controls, and T represents
colorectal carcinoma tumor patients. Coomassie Brilliant Blue staining
indicated that equal amounts of proteins were loaded onto SDS-PAGE
gels. The ratio of HMGB1:CBB was calculated by TINA program and
depicted under the images.
doi:10.1371/journal.pone.0034318.g001
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HMGB1 is a potential diagnostic biomarker for colorectal cancer.
For the median values, the difference of these two groups were not
significant (P = 0.1141), though both of these levels were followed
by normal distribution by Shapiro-Wilk test. In addition to this,
the statistical power of these values was 0.4202, which results from
small scale samples. To acquire more than 80% of statistical
power, more than 12 cases of healthy controls and tumor cases
were needed. Although we could not obtain statistically meaning-
ful data, difference between two groups by mean value (1.2 fold
increase, p= 0.06 by Welch’s t-test) was evident. Based on these
data, we performed the HMGB1 value in a large series of clinical
samples by ELISA assay.
Characteristics of the subjects
To test the serum values of HMGB1 and CEA from our
collected blood sample sets, we have analyzed the 219 tumor cases
according to several clinicopathologic features including age,
gender, TNM stage, tumor location, size of tumor mass, status of
microsatellite instability, status of recurrence, time of survival,
tumor differentiation, and tumor metastasis (Table 2)
Table 2. Clinicopathologic features of 219 colorectal cancer patients according to serum HMGB1 levels.
Serum HMGB1 level (ng/ml) Serum CEA level (ng/ml)
Feature .58.2a #58.2 P .5b #5 P
1. Age (y) 0.4551 0.0066
,60 23 78 17 84
$60 21 97 40 78
2. Gender 0.993 0.96
M 28 109 35 102
F 16 66 22 60
3. Stage 0.0018 ,0.0001
I 14 20 3 31
II 18 65 18 65
III 7 63 15 55
IV 5 27 21 11
4. Location 0.5443 0.7789
Colon 25 88 28 85
Rectum 19 87 29 77
5. Size (cm) 0.1132 0.016
,5 12 73 14 71
$5 32 102 43 91
6. MSIc status 0.8295 0.2728
High 8 27 6 29
MSSd and low 36 148 51 133
7. Recur status 0.551 0.127
No Recur 33 131 37 127
Local 3 6 3 6
Systemic 8 38 17 29
8. Time of survival 0.4526 ,0.0001
,3 years 6 35 22 19
$3 years 38 140 35 143
9. Differentiation 0.1349 0.1493
poor 2 11 3 10
moderate 32 141 50 123
well 10 23 4 29
10. metastasise 0.1974 ,0.0001
metastatic 10 60 32 38
nonmetastatic 34 115 25 124
aThe cutoff value of HMGB1 was determined by MedCalc software using a previously published algorithm [44].
bThe cutoff value of CEA was determined by the level practically used to diagnose CRC [39,45,46].
cMSI, microsatellite-instable cancer.
dMSS, microsatellite-stable cancer.
eThe information of tumor metastasis was followed up over 5 years after surgery.
doi:10.1371/journal.pone.0034318.t002
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Increased serum HMGB1 levels in colorectal cancer
patients
ELISAs were performed to evaluate serum HMGB1 levels in a
large series of colorectal cancer patients. We selected serum from
colorectal cancer 219 patients and 75 healthy subjects without
evidence of carcinoma. The average serum HMGB1 levels were
1.5-fold higher (P = 0.03) in colorectal cancer patients; the mean
serum concentration was 58.86126.2 ng/mL in colorectal cancer
patients and 39.7616.2 ng/mL in control subjects (Figure S2A).
The median value was 38.3 (10.3, 92.1) ng/mL for healthy control
subject, and 33.3 (1.3, 1350.0) ng/mL for cancer patients by
Mann-Whitney test (P = 0.2638). To make all of the values more
understandable by reducing the variation, we have replaced the
raw data by logarithmic function and the transformed data was
shown in Figure 2A. There were also significant differences in the
serum levels of CEA between patients with colorectal cancer and
control subjects (P = 0.02); the mean serum concentration was
18.36100.8 ng/mL in patients with colorectal carcinoma and
1.961.8 ng/mL in control subjects (Figure S2B). The median
value was 1.2 (0.1, 10.2) ng/mL for healthy control subjects, and
2.2 (0, 1274.6) ng/mL in cancer patients (P,0.0001). The values
were applied by logarithmic function, and the transformed values
were shown in Figure 2B. When we compared the median value of
HMGB1 between control subjects and cancer patients, we
couldn’t identify statistical significance between two groups,
implying high variation of the values for HMGB1 in our
population may affect the mean value.
To analyze the diagnostic value of serum HMGB1, we analyzed
serum HMGB1 levels according to the clinicopathologic features
of 219 patients. Serum HMGB1 levels were elevated in stage I
cancer compared to those of CEA, whereas serum CEA levels
were higher in advanced-stage cancer (Figures S2C and D). The
values were applied by logarithmic function, and the transformed
values were shown in Figures 2C and D. As expected, the overall
diagnostic value according to tumor stage was correlated to these
Figure 2. Serum HMGB1 levels are increased in colorectal cancer patients. The sera of 219 cancer patients were screened using HMGB1
ELISA, and the findings were compared with those of 75 non-cancerous healthy controls. Serum CEA levels were also measured in both groups. Each
serum value was transferred to natural logarithm to draw a data comparison plot. (A) Serum HMGB1 levels were 1.5-fold higher in cancer patients
than in healthy controls (the mean serum concentrations were 58.86126.2 ng/mL in colorectal cancer patients and 39.7616.2 ng/mL in control
subjects). The P-value was calculated by the Welch’s t-test ( = 0.03) (B) Serum CEA levels were elevated in cancer patients compared to those in
healthy controls (the mean serum concentrations were 18.36100.8 ng/mL in patients with colorectal carcinoma and 1.961.8 ng/mL in control
subjects). The P-value was calculated by the Welch’s t-test ( = 0.02) (C) HMGB1 concentrations were depicted according to different tumor stages. (D)
CEA concentrations were depicted according to different tumor stages. CEA levels were elevated in advanced tumor stages.
doi:10.1371/journal.pone.0034318.g002
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results; the P values of HMGB1 and CEA according to TNM stage
were 0.0018 and less than 0.0001, respectively. This result suggests
that these two molecules might be complementary for diagnosing
colorectal cancer. Unlike to our expectation, our data did not
show the close relationship between tumor metastasis and
HMGB1 levels, although previous reports suggested the relation-
ship between HMGB1 and tumor metastasis [20]. The elevated
CEA levels were closely associated with tumor metastasis
(P,0.0001) in accordance with previous reports [26].
To evaluate the diagnostic value of HMGB1 secretion levels, we
used ROC methods to calculate the sensitivity and specificity of
HMGB1 and CEA. We determined the 58.2 ng/mL as the cutoff
value of HMGB1 using a statistical program (MedCalc). For CEA,
we used 5 ng/mL as the cutoff value. We encode serum HMGB1
and CEA levels according to their acquired cutoff value (58.2 ng/
mL vs. 5 ng/mL, respectively), and represent ROC curve by re-
encoded value. The diagnostic specificity of HMGB1 secretion
levels was better than that of CEA, but the sensitivity of HMGB1
was lower (Figure 3A); the sensitivity and specificity of HMGB1
were 20.1% and 96%, respectively, compared to 25.6% and
90.7%, respectively, for CEA (Figure 3B). Because serum HMGB1
levels were high in early stages of colorectal cancer, we combined
the diagnostic values of these two markers to increase the accuracy
of colorectal cancer diagnosis in early stages. Figure 3C shows that
the overall diagnostic value of combination of HMGB1 and CEA
had improved sensitivity, but the specificity was not higher than
that of CEA or HMGB1 alone (the sensitivity and specificity were
42% and 86.7%, respectively). However, the overall AUC was
increased when we combine these two marker; the overall AUCs
were 0.580 for HMGB1, 0.581 for CEA, and 0.643 for
combination of HMGB1 and CEA, respectively. All of the
diagnostic values were summarized in Table 3. These data
indicate that the combination of HMGB1 and CEA significantly
elevated the diagnostic accuracy for CRC. In our data, the
diagnostic sensitivity was significantly increased when these two
markers were combined while the specificity was slightly
decreased. To assess the diagnostic accuracy by increasing
sensitivity, we have compared the sensitivity for HMGB1, CEA,
and the combination of these two markers at a fixed specificity.
When the specificity was fixed at 90%, the sensitivity of HMGB1,
CEA, and the combination of HMGB1 and CEA was slightly
elevated. In addition to this, the sensitivity of combination of
HMGB1 and CEA was significantly increased compared to
HMGB1 or CEA alone at the 80% of specificity (Figure S3). These
results indicate that the combination of HMGB1 and CEA has a
benefit for the improvement of diagnostic accuracy by increasing
diagnostic sensitivity despite the specificity was slightly decreased.
In stage I cancers, the diagnostic value of HMGB1 was much
higher than that of CEA; the sensitivity and specificity of HMGB1
were 41.2% and 96% and the sensitivity and specificity of CEA
Figure 3. ROC curves generated with serum CEA and HMGB1 levels. To certify the utility of HMGB1 in the diagnosis of colorectal cancer, we
used the ROC method to determine cutoff values. (A) ROC curve for HMGB1. At the cutoff value of 58.2 ng/mL, the sensitivity and specificity were
20.1% and 96%, respectively. Overall AUC was 0.580. (B) ROC curve for the CEA. The sensitivity and specificity were 25.6% and 90.7%, respectively.
Overall AUC was 0.581. (C) ROC curve for the combination of HMGB1 and CEA. The sensitivity and specificity were 42.0% and 86.7%, respectively.
Overall AUC was 0.643. (D) Comparison of combination of HMGB1 and CEA with CEA alone for stage I colorectal cancer. The overall AUC was higher
for the combination of these two markers than for CEA alone. All of the reference lines were determined when the AUC was 0.5.
doi:10.1371/journal.pone.0034318.g003
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were 5.9% and 90.7%, respectively, while the AUC of HMGB1
and CEA in stage I were 0.569 and 0.517, respectively. To
compensate the low diagnostic value of CEA in early stage cancer,
we have combined those two markers, and the sensitivity of these
two markers in combination was much better than that of CEA
alone; the sensitivity and specificity of the combination were 47%
and 86.7%, respectively (the sensitivity and specificity of CEA
were 5.9% and 90.7% for stage I, respectively; Figures 3D). The
low sensitivity of CEA in stage I was in accordance with previous
report [27]. In our study, only 2 of 34 patients were shown in CEA
levels over 5 ng/mL in stage I cancer. These data suggest that the
combination of HMGB1 and CEA could increase the diagnostic
accuracy for colorectal cancer, especially in early tumor stages.
Correlation of HMGB1 and CEA according to the serum
levels
To assess the relationship between serum CEA and HMGB1
levels, we calculated Spearman’s correlation coefficient. For 75
healthy controls group, the correlation coefficient constant r was
0.414 (P= 0.0002) demonstrating these two markers were
positively correlated with each other in healthy control subjects
(Figure 4A). For 219 cancer patients group, the correlation
coefficient constant r was -0.0275 (P= 0.6858) demonstrating these
two markers seems to be negatively correlated with each other
despite its low accuracy by P-value. All of these data suggests that
CEA and HMGB1 are correlated with positive tendency in control
subject, but does with negative tendency in cancer patients. These
results imply that the combination of these two markers can be a
good model for the diagnosis colorectal carcinomas.
Relationship between serum HMGB1 levels and patient
survival
We also performed survival analysis according to the serum
levels of HMGB1 and CEA by the Kaplan-Meier method. We
analyzed the prognostic significance using cutoff values of
58.2 ng/mL for HMGB1 and 5 ng/mL for CEA (Figure S4). In
the log rank test, the serum HMGB1 level did not correlate with
prognosis (P = 0.336), but the serum CEA level was correlated with
the survival rate of colorectal cancer patients (P,0.0001).
Discussion
In this study, we evaluated serum HMGB1 concentrations in
219 patients with colorectal carcinoma and compared them to the
concentrations in healthy control subjects. We identified that the
concentration of serum HMGB1 was higher in patients with
colorectal cancer than in normal healthy subjects. Our findings
suggest that serum HMGB1 levels can be used as a novel
diagnostic marker.
Colorectal cancer (CRC) is the third most common malignancy
in the world. In Korea, CRC is the fourth leading cause of cancer-
related death, and its incidence continues to increase [28]. The
risk of recurrence and subsequent death due to CRC is closely
related to the stage of the disease at the time of primary diagnosis.
Serological biomarkers can be analyzed relatively easily and
economically and therefore have the potential to greatly enhance
screening acceptance. Various serum markers for CRC are
available, among which CEA is the most commonly used marker
[29]. However, this marker lacks the sensitivity and specificity
needed to screen an average risk population [30]. Therefore, new
biomarkers of cancer are needed that will further enhance
detection of the disease and trigger a follow-up colonoscopy.
An increasing body of evidence suggests that HMGB1 is
associated with tumor metastasis and poor prognosis [9,10],
making HMGB1 an attractive target as a tumor biomarker.
Considering the known role of HMGB1, secreted HMGB1 can be
involved in tumor metastasis through binding cell surface receptors
including RAGE. We previously demonstrated that HMGB1 is
translocated to the cytoplasm and secreted by cancer cells [17].
HMGB1 secreted from tumor cells can be involved in tumor
progression, particularly metastasis. The evaluation of serum
HMGB1 levels is essential for evaluating both the diagnostic
significance of HMGB1 in colorectal cancer and the inhibition of
cancer progression by blocking serum HMGB1. Several reports
indicated that the serum HMGB1 level was elevated in patients
with various types of cancer and its diagnostic values were
evaluated in some tumors [20,23]. To our knowledge, this is the
first report demonstrating higher serum HMGB1 levels in
colorectal cancer patients. The secreted serum HMGB1 is
expected to be derived from cancer cells or immune cells in the
peritumoral area. In cancer, the roles of HMGB1 have been
suggested on the basis of its roles in immune cells. HMGB1 has
been reported to be related to poor prognosis in cancer patients
[9,10]. Previous results suggested that HMGB1 is an important
mediator for precancerous disease, and therefore, HMGB1 can
contribute to the early development of cancer, tumor growth, and
invasion of cancer cells [31]. Although HMGB1 plays important
roles in immune cells and cancer cells, differences exist in the
biologic roles of HMGB1 between cancer and immune cells. First,
HMGB1 is acutely translocated and secreted by immune cells in
response to TNF-a, IL-1b, or LPS stimulation [32,33,34,35],
whereas cancer cells have no known stimuli for translocation and
secretion. Instead, cancer cells are known to possess cytoplasmic
HMGB1 in its resting state. HMGB1 has known to have diverse
functions in cancer including anti-apoptosis, cell-cycle progression,
cell growth, invasion, migration, and metastasis [36,37]. In
addition to this, HMGB1 can be strongly secreted by immune
activation. Because there are no known tools differentiating
secreted HMGB1 between immune cells and cancer cells, we
couldn’t discriminate the source of HMGB1 secretion in our
clinical samples. The secreted HMGB1 from immune cells might
cause elevation of HMGB1 from the early stage cancers.
Alternatively, HMGB1 was known to be important in malignant
cell transformation. In melanoma, HMGB1 is overexpressed in
tumor compared to normal melanocyte, leading to malignant
transformation and melanoma development [38]. Furthermore,
Table 3. Summary of receiver operating curve methods for HMGB1 and CEA.
Specificity Sensitivity Significant level P Area under the curve
HMGB1 96 20.1 ,0.0001 0.580
CEA 90.7 25.6 0.0003 0.581
HMGB1+CEA 86.7 42.0 ,0.0001 0.643
doi:10.1371/journal.pone.0034318.t003
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HMGB1 functions as a anti-apoptotic oncoprotein by leading to
NF-kB and the target gene product c-IAP (inhibitor of apoptosis)
[24]. These reports suggest that HMGB1 could be an oncoprotein
for contribution to the tumor development and formation,
implying that HMGB1 could be highly secreted in early tumor
disease. The identification of the cellular origin of serum HMGB1
will be helpful for the diagnostic utility of serum HMGB1 in the
future.
Unlike CEA, elevated serum HMGB1 was also frequently
observed in early-stage colorectal cancer. These findings suggest
that HMGB1 is useful as a supportive diagnostic marker in
colorectal cancer. To evaluate the diagnostic significance of
HMGB1, we compared HMGB1 levels with CEA levels and found
that the combination of these two markers increases the diagnosis
rate of early stage colorectal carcinomas. CEA is a glycoprotein
involved in cell adhesion that is normally produced during fetal
development. However, its production stops before birth, and
CEA is not usually present in the blood of healthy adults.
However, it has been found that serum from people with
colorectal, gastric, pancreatic, lung, and breast carcinoma has
higher levels of CEA than healthy people. In addition, CEA also
has reported utility in monitoring the prognosis of tumor patients
[39]. The previously reported sensitivity and specificity of CEA
were approximately 20% to 40% and 70% to 100%, respectively
[40]. In accordance with previous reports, the serum CEA level is
related to tumor progression, and, therefore, evaluating serum
CEA has limited value in detecting early-stage colorectal
carcinomas. We presented the ROC curve for HMGB1 alone in
Figure 3A. The sensitivity and specificity of HMGB1 were 20.1%
and 96.0%, respectively, and the AUC was 0.580. According to
the ROC curve for CEA, the diagnostic sensitivity and specificity
were 25.6% and 90.7%, respectively, and the AUC was 0.581
(Figure 3B). We have demonstrated that the diagnostic efficacy
was improved using the combination of HMGB1 and CEA
compared to that of CEA or HMGB1 alone. The AUC for the
combination of HMGB1 and CEA was 0.643, and this value was
higher than that of CEA alone (0.581) or HMGB1 alone (0.580).
We also demonstrated that the diagnostic efficacy was improved,
particularly in earlier stages, as the AUC for the combination of
HMGB1 and CEA was 0.669 showing great improvement for
AUC result (the AUC for HMGB1 was 0.569 and the AUC for
CEA was 0.517, respectively). We, therefore suggest that the
serum HMGB1 level is valuable in colorectal carcinoma detection,
especially in combination with CEA. In addition, there was
evidence that HMGB1 secretion is related to the outcome of
chemoradiotherapy [41], but our study only had two patients to
investigate this issue. Further investigation of the patients including
those who received preoperative chemoradiotherapy might be
helpful to validate the diagnostic significance of HMGB1.
The variation of HMGB1 secretion among individuals occurred
not only in the cell lines but also in the clinical samples. In the
tumor tissues, we found that most of the tumor cells contain
variable amount of cytoplasmic HMGB1, while no cytoplasmic
HMGB1 was detected in normal epithelial and stromal cells. In
the cell line, we have chosen the CCD18Co human colonic
fibroblast cell line as a normal control cell line because HMGB1
was scarcely translocated and secreted in this cell line in our
previous study [17,42]. In contrast to the non-neoplastic cell lines,
differences in the secretion of HMGB1 were present and may be
related to the diverse functions of HMGB1 [33]. RKO cell line
among the cancer cells showed very low secretion of HMGB1 and
this result corresponds to our previous result [42]. The specific
mechanism for this low HMGB1 secretion is not known. HMGB1
levels were extremely high in two patients (1.4 and 1.1 mg/mL,
respectively). To assess the effect of these two cases, we reanalyzed
the data after excluding these two cases. When we excluded these
two cases, the average value of HMGB1 was 1.2-fold higher in
healthy control subjects. This changed the diagnostic values of the
ROC results: the sensitivity and specificity of HMGB1 were 54.4%
and 61.3%, respectively. Despite the reduction of specificity,
HMGB1 still exhibits significantly high sensitivity than CEA
(sensitivity, 25.8%; specificity 90.7%), thus suggesting that
Figure 4. Correlation plot generated with serum CEA and HMGB1 levels. To assess the relationship between serum CEA and HMGB1 levels
for the correlation, we used the Spearman’s rho method to determine the correlation coefficient r. (A) Correlation plot of 75 healthy subjects for CEA
and HMGB1 serum expression levels. The correlation coefficient r was 0.414 (P = 0.0002) for the two values in healthy control group showing these
two markers were positively correlated with each other. The X axis represents CEA levels and the Y axis represents HMGB1 levels, respectively. (B)
Correlation plot of 219 colorectal carcinoma patients for CEA and HMGB1 serum expression levels. The correlation coefficient r was 20.0275
(P = 0.6858) for the two values in cancer patients demonstrating that these two markers seems to be negatively correlated with each other despite its
low accuracy for this tendency. The X axis represents CEA levels and the Y axis represents HMGB1 levels, respectively.
doi:10.1371/journal.pone.0034318.g004
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HMGB1 is a useful biomarker to improve the diagnostic
sensitivity.
Although high and widespread overexpression of HMGB1 is
found in tumor cells [17,22], only 20% of all patients had serum
HMGB1 levels higher than the cutoff value of ROC curve
(58.2 ng/mL). The reason for such difference could be explained
by a diverse source of serum HMGB1. HMGB1 is secreted from
cancer cells and inflammatory cells. This may results in false-
positive elevation of HMGB1 in control subjects. To validate a
more accurate diagnostic value of HMGB1, a large scale study
including inflammatory disease should be performed in the future.
We have analyzed the colon cancer patient survival according to
the serum HMGB1 level. We could not find any correlation
between serum HMGB1 level and patient survival, whereas serum
CEA level was correlated to poor patient survival. Serum CEA
levels increased with increasing TNM stage, implying that CEA
was related to higher stages of colorectal cancer. Although
HMGB1 was reported to be related with poor prognosis in
colorectal carcinoma tissues in an earlier report [43], we could not
compare HMGB1 levels in cancer tissue by immunohistochem-
istry because most of the tumor cells exhibited HMGB1
overexpression. In the survival analysis using serum HMGB1
levels, no correlation was found between serum HMGB1 levels
and patient survival. Further study should be performed to verify
the relationship between serum HMGB1 levels and prognostic
significance.
Supporting Information
Figure S1 HMGB1 expression in colorectal cancer
tissues. A representative colorectal cancer tissue was stained
with anti-HMGB1 and counterstained with hematoxylin. HMGB1
was expressed in both tumor cells and the surrounding normal
cells. Magnified images are shown on the right part of the figure,
which indicated that HMGB1 expression was restricted to the
nuclei of normal mucosal cells, whereas cytoplasmic HMGB1
expression was evident in tumor cells.
(TIF)
Figure S2 Serum HMGB1 levels are increased in
colorectal cancer patients. The sera of 219 cancer patients
were screened using an HMGB1 ELISA, and the findings were
compared with those of 75 non-cancerous healthy controls. Serum
CEA levels were also measured in both groups. (A) Serum
HMGB1 levels were 1.5-fold higher in cancer patients than in
healthy controls (the mean serum concentration was 58.86
126.2 ng/mL in colorectal cancer patients and 39.7616.2 ng/
mL in control subjects). P-value was calculated by Welch’s t-test
( = 0.03) (B) Serum CEA levels were elevated in cancer patients
compared to those in healthy control (the mean serum
concentration was 18.36100.8 ng/mL in patients with colorectal
carcinoma and 1.961.8 ng/mL in control subjects). P-value was
calculated by Welch’s t-test ( = 0.02) (C) HMGB1 concentrations
were depicted according to different tumor stages. (D) CEA
concentrations were depicted according to different tumor stages.
CEA levels were elevated in advanced tumor stages.
(TIF)
Figure S3 The comparison of ROC curve at a fixed
specificity. To analyze the impact on the increase of diagnostic
accuracy by increasing diagnostic sensitivity, we have analyzed the
diagnostic sensitivity at a fixed specificity. (A) The ROC curve for
the HMGB1. The lines depicted on the ROC curve showed the
sensitivity of y axis at a fixed specificity of 80% (**) and 90% (*),
respectively. (B) The ROC curve for the CEA. The lines depicted
on the ROC curve showed the sensitivity of y axis at a fixed
specificity of 80% (**) and 90% (*), respectively. (C) The ROC
curve for the combination of HMGB1 and CEA. The lines
depicted on the ROC curve showed the sensitivity of y axis at a
fixed specificity of 80% (**) and 90% (*), respectively.
(TIF)
Figure S4 Survival analysis for colorectal cancer pa-
tients according to serum HMGB1 levels. The survival rate
of colon cancer patients according to serum HMGB1 or CEA
secretion was analyzed by the Kaplan-Meier method. (A) The
prognostic significance of CEA at the cutoff level of 5 ng/mL.
According to the log rank test, serum CEA levels were predictive
of survival for colorectal cancer patients (P,0.0001). (B) The
prognostic significance of HMGB1 at the cutoff level of 58.2 ng/
mL. According to the log rank test, serum HMGB1 levels were not
predictive of prognosis (P = 0.336).
(TIF)
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